The Food and Drug Administration today withdrew approval for Makena and its generics, citing a confirmatory study that did not verify clinical benefit. Makena had been approved under the FDA’s accelerated approval pathway to reduce the risk of preterm birth in women pregnant with one baby who have a history of spontaneous preterm birth. Makena and its generics cannot lawfully be distributed in interstate commerce, effective immediately. FDA is aware that some products have already been distributed, so health care providers should talk to their patients, if applicable.

Related News Articles

Blog
Since 2018, Black Maternal Health Week has been a national observance from April 11–17. This annual observance was created by the Black Mamas Matter Alliance…
Headline
Two caregivers discuss how Colorado’s San Luis Valley Hospital creatively maximizes its resources to continue to deliver obstetric services to the families and…
Headline
As part of a yearlong series devoted to rural hospitals and health systems in America, two experts from Intermountain Health discuss their "First 1,000 Days of…
Headline
The House March 5 voted 382-12 to pass the AHA-supported Preventing Maternal Deaths Reauthorization Act (H.R. 3838), bipartisan legislation that would…
Headline
The House Energy and Commerce Subcommittee on Health Feb. 29 held a hearing on legislative proposals to expand access to treatment for patients with rare…
Headline
Part of a special series exploring how hospitals and health systems are addressing the medical complications that can accompany pregnancy, this podcast shares…